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Left Atrial Function Predicts Heart Failure
Hospitalization in Subjects With Preserved
Ejection Fraction and Coronary Heart Disease
Longitudinal Data From the Heart and Soul Study
Christine C. Welles, MD,*† Ivy A. Ku, MD,‡ Damon M. Kwan, MD,§ Mary A. Whooley, MD,*†
Nelson B. Schiller, MD,*† Mintu P. Turakhia, MD, MAS¶
San Francisco, Los Angeles, Palo Alto, and Stanford, California
Objectives This study sought to determine whether left atrial (LA) dysfunction predicts heart failure (HF) hospitalization in
subjects with preserved baseline ejection fraction (EF).
Background Among patients with preserved EF, factors leading to HF are not fully understood. Cross-sectional studies have
demonstrated LA dysfunction at the time of HF, but longitudinal data on antecedent atrial function are lacking.
Methods We performed resting transthoracic echocardiography in 855 subjects with coronary heart disease and EF
50%. Left atrial functional index (LAFI) was calculated as ([LA emptying fraction  left ventricular outflow
tract-velocity time integral] / [indexed LA end-systolic volume]), where LA emptying fraction was defined as (LA
end-systolic volume  LA end-diastolic volume) / LA end-systolic volume. We used Cox models to evaluate the
association between LAFI and HF hospitalization.
Results Over a median follow-up of 7.9 years, 106 participants (12.4%) were hospitalized for HF. Rates of HF hospitaliza-
tion were inversely proportional to quartile (Q) of LAFI: Q1, 47 per 1,000 person-years; Q2, 18.3; Q3, 9.6; and
Q4, 5.3 (p  0.001). Each standard deviation decrease in LAFI was associated with a 2.6-fold increased hazard
of adverse cardiovascular outcomes (unadjusted hazard ratio: 2.6, 95% confidence interval: 2.1 to 3.3, p 
0.001), and the association persisted even after adjustment for clinical risk factors, N-terminal pro–B-type natri-
uretic peptide, and a wide range of echocardiographic parameters (adjusted hazard ratio: 1.5, 95% confidence
interval: 1.0 to 2.1, p  0.05).
Conclusions Left atrial dysfunction independently predicts HF hospitalization in subjects with coronary heart disease and preserved
baseline EF. The LAFI may be useful for HF risk stratification, and LA dysfunction may be a potential therapeutic
target. (J Am Coll Cardiol 2012;59:673–80) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.012H
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affecting 5.8 million people in the United States, with
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eart failure is the number 1 cause of hospitalization in
ersons over the age of 65 years (2), and approximately
ne-half of all HF hospitalizations occur in patients who
ave HF with preserved ejection fraction (HFpEF) (3,4).
atients with HFpEF have increased mortality and
orbidity, similar to that of patients with HF and
educed EF (5,6). Although medical and device therapies
ave improved survival for patients with low EF, large
andomized trials of traditional HF therapies such as
ngiotensin-blockade have not demonstrated a survival
enefit in HFpEF (7–9). The underlying pathophysiol-
gy of HFpEF is complex (10), and factors precipitating
F events in patients with preserved EF are not well
nderstood (11).
Classically, HFpEF has been attributed to diastolic dys-unction and left ventricular (LV) stiffness, resulting in
Fe
d
p
p
m
o
a
p
t
t
v
d
p
(
i
L
v
v
a
t
t
s
i
w
v
0
i
C
o
a
i
a
i
t
c
t
d
w
m
d
p
674 Welles et al. JACC Vol. 59, No. 7, 2012
Left Atrial Function and Heart Failure February 14, 2012:673–80elevated LV end-diastolic pres-
sures (12). However, diastolic
dysfunction and LV hypertrophy
are also common in patients with
hypertension, many of whom never
have clinical HF (13,14). Therefore,
additional discriminating features to
identify subjects at highest risk of
HF development are of interest both
from a clinical and from a patho-
physiologic standpoint.
Left atrial (LA) remodeling
due to overt or subclinical atrial
volume or pressure overload
could result in decreased atrial
systolic function. Atrial dysfunc-
tion could lead to impaired atrial
emptying, which decreases car-
diac output, or it could be an
early indicator of cardiac conges-
tion or failure even when EF is
preserved. Cross-sectional stud-
ies have demonstrated an associ-
ation between LA dysfunction
and HFpEF (14), but longitudi-
nal studies to assess whether LA
dysfunction predicts future HF
events are lacking. Therefore,
we evaluated the longitudinal association of LA function,
as assessed by the left atrial functional index (LAFI), to
HF hospitalization in subjects with prevalent coronary
heart disease and preserved baseline EF.
Methods
Participants. The Heart and Soul Study is a prospective
cohort study originally designed to investigate psychosocial
factors and health outcomes in patients with stable coronary
heart disease. Details regarding recruitment methods and
study design have been previously published (15). Briefly,
between September 2000 and December 2002, we recruited
1,024 out-patients with stable coronary heart disease from 2
Veterans Administration Medical Centers (Palo Alto and
San Francisco), 1 university medical center (University of
California, San Francisco), and 9 public health clinics in
the Community Health Network of San Francisco. Eli-
gible participants met 1 or more of the following criteria:
1) history of myocardial infarction; 2) evidence of at least
50% stenosis in 1 or more coronary vessels on cardiac
catheterization; 3) evidence of exercise-induced ischemia by
treadmill electrocardiogram or nuclear perfusion stress im-
aging; or 4) a history of coronary revascularization. We
excluded subjects with a history of myocardial infarction in
the previous 6 months, inability to walk 1 block, or planning
Abbreviations
and Acronyms
AF  atrial
fibrillation/flutter
CI  confidence interval
E/A ratio  ratio of early
rapid filling to late atrial
contraction
EF  ejection fraction
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
HR  hazard ratio
LA  left atrial/atrium
LAFI  left atrial functional
index
LAVI  left atrial volume
index
LV  left
ventricle/ventricular
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
PASP  pulmonary artery
systolic pressure
VTI  velocity time integralto move out of the local area within 3 years. cOf the 1,024 original study subjects, we excluded the
following participants: 110 with baseline EF50%, 15 with
moderate or greater valvular disease, 40 with missing echo-
cardiographic data, and 4 lost to follow-up. The remaining
855 participants are the subjects of this analysis. This study
was approved by the institutional review board, and all
participants provided written, informed consent.
Measurements. PREDICTOR VARIABLE, LEFT ATRIAL
UNCTION INDEX. We performed resting transthoracic
chocardiography in 855 participants with coronary heart
isease and preserved EF (50%). These studies were
erformed in the standard left lateral recumbent and supine
ositions using an Acuson Sequoia ultrasound system (Sie-
ens Medical Solutions, Mountain View, California). We
btained standard 2-dimensional parasternal short-axis and
pical 2- and 4-chamber views during held inspiration, and
lanimetered these with a computerized digitization system
o determine end-diastolic and end-systolic LV volumes by
he biplane method of disks. The moments of first mitral
alve opening and closing were used to determine end-
iastolic and end-systolic LV volumes.
The derivation and validation of the LAFI has been
reviously described (16). The LAFI was calculated as:
[LA emptying fraction  LV outflow tract-velocity time
ntegral (VTI)] / [LA end-systolic volume index)], where
A emptying fraction was defined as: (LA end systolic
olume  LA end-diastolic volume) / LA end-systolic
olume (Fig. 1). All echocardiograms were performed using
standardized protocol by 1 of 2 trained and experienced
echnicians.
A single experienced reader blinded to clinical informa-
ion (N.B.S.) interpreted all studies and verified the mea-
urements used for the calculation of LAFI. The reproduc-
bility of LAFI by this reader has been previously described
ith Bland-Altman analyses, which revealed no significant
ariation (intraobserver reproducibility: mean difference
.0059, 95% confidence interval [CI]: 0.015 to 0.012;
nterobserver reproducibility: mean difference 0.0017, 95%
I: 0.025 to 0.013) (16).
OUTCOME VARIABLE, HF HOSPITALIZATION. The primary
utcome was time to first HF hospitalization. We conducted
nnual follow-up interviews with participants or their proxy to
nquire about interval hospitalization for “heart trouble.” For
ny reported event, we retrieved medical records, which 2
ndependent and blinded physician adjudicators reviewed. If
he adjudicators agreed on the outcome classification, their
lassification was binding. In the event of a disagreement, a
hird blinded adjudicator was consulted.
We defined HF as hospitalization for a clinical syn-
rome based on the Framingham congestive HF criteria,
hich require validation of 2 major or 1 major plus 2
inor criteria. Major criteria are paroxysmal nocturnal
yspnea, orthopnea, elevated jugular venous pressure,
ulmonary rales, third heart sound, cardiomegaly on
hest radiograph, pulmonary edema on chest radiograph,
t
r
a
p
j
f
c
a
i
d
(
b
u
b
d
v
c
p
a
p
E
v
o
(
c
d
a
l
3
fi
c
a
i
e
r
i
a
f
p
v
r
D
P
675JACC Vol. 59, No. 7, 2012 Welles et al.
February 14, 2012:673–80 Left Atrial Function and Heart Failureweight loss 4.5 kg in 5 days in response to HF therapy;
minor criteria are peripheral edema, night cough, dyspnea
on exertion, hepatomegaly, pleural effusion, heart rate
120 beats/min (13,17).
OTHER MEASUREMENTS. Age, sex, race, and medical his-
ory (including history of HF) were determined by self-
eported questionnaire. We measured height and weight,
nd calculated body mass index (kg/m2). Systolic blood
pressure, diastolic blood pressure, and heart rate were
measured in the supine position after 5 min of rest. We
measured serum creatinine, low-density lipoprotein, high-
density lipoprotein, and N-terminal pro–B-type natriuretic
peptide (NT-proBNP) from fasting blood samples drawn at
the baseline study appointment. Estimated glomerular func-
tion was calculated by the abbreviated (4-variable) Modifi-
cation of Diet and Renal Disease Study formula, as follows:
estimated GFR  186  (serum creatinine1.154) 
(age0.203)  (0.742 if female)  (1.21 if black) (18). We
erformed standard 12-lead electrocardiograms on all sub-
ects at the time of enrollment and again after 5 years of
ollow-up. Two independent, blinded physicians adjudi-
ated the rhythm of all electrocardiograms. In the event of
disagreement, a third adjudicator was consulted.
From the resting echocardiograms, the left atrial volume
ndex (LAVI) was defined as LA end-systolic volume
ivided by body surface area. The LVEF was calculated as
end-diastolic volume minus end-systolic volume) divided
y end-diastolic volume (19). The LV mass was calculated
sing the truncated-ellipse method (20) and indexed to
ody surface area. We defined 3 categories of diastolic
ysfunction on the basis of mitral flow ratios of peak
elocities at early rapid filling and late filling at atrial
ontraction (E/A ratio) and systolic or diastolic dominant
ulmonary venous flow: 1) impaired relaxation, defined as
n E/A ratio of 0.75 or less and systolic dominant
ulmonary venous flow; 2) pseudonormal, defined as an
/A of 0.75 to 1.5 and diastolic dominant pulmonary
enous flow; and 3) restrictive, defined as an E/A of 1.5
r greater and diastolic dominant pulmonary venous flow
      = LA em
           LA
LAFI units = (cm) x (m2)/cc (i.e. units c
LVOT VTI = velocity time integral of th
LAESV = maximal left atrial volume in
BSA = body surface area 
LAFI
Figure 1 Derivation of the LAFI
The left atrial functional index (LAFI) is an index of atrial function that incorporates
[VTI]), atrial reservoir function (left atrial emptying fraction) and indexed atrial size
ple echocardiographic measure of left atrial function that extends information from
reservoir function, and body habitus. BSA  body surface area.13). We have previously found differences in rates ofardiovascular outcomes in these 3 categories of diastolic
ysfunction (no diastolic dysfunction, impaired relax-
tion, pseudonormal/restrictive) (21); therefore, we ana-
yzed diastolic dysfunction as an ordinal variable at these
levels. Because 5% of the study sample had restrictive
lling, the pseudonormal and restrictive groups were
ombined for analysis.
To determine presence of inducible ischemia at baseline,
ll participants underwent exercise treadmill testing accord-
ng to a standard Bruce protocol with continuous 12-lead
lectrocardiogram monitoring. We performed echocardiog-
aphy immediately before and after exercise. We defined
nducible ischemia as the presence of 1 new wall motion
bnormality at peak exercise.
We estimated pulmonary artery systolic pressure (PASP)
rom echocardiography as tricuspid regurgitation gradient
lus right atrial pressure. The tricuspid regurgitation jet was
isualized with color flow mapping, and the tricuspid
egurgitation gradient was measured with continuous-wave
oppler. We used the modified Bernoulli equation (delta
 4v2) to calculate gradients from velocities. Right atrial
pressure was estimated from the size and respiratory varia-
tion of flow in the inferior vena cava.
Statistical analysis. Participants were divided into quar-
tiles based on their LAFI. We compared differences in
baseline characteristics across quartiles using chi-square
tests for categorical variables and 1-way analysis of
variance for continuous variables. Cumulative event-free
survival was measured by the method of Kaplan-Meier,
and unadjusted differences were compared using the
log-rank test. We performed multivariate Cox regression
to compare the rate of HF hospitalization across quartiles
of LAFI. To determine the independent prognostic value
of LAFI, we used incremental multivariate models ad-
justing for covariates demonstrating an association with
LAFI at p  0.1. We adjusted for age, sex, and race
(model 1); plus tobacco use, prior revascularization,
history of HF, atrial fibrillation, estimated glomerular
filtration rate, low-density lipoprotein cholesterol, angio-
ing fraction x LVOT VTI (cm) 
 indexed to BSA (cc/m2) 
l out) 
 ventricular outflow tract (cm) 
systole (cc) 
gues of cardiac output (left ventricular outflow tract [LVOT] velocity time integral
al left atrial volume in end systole [LAESV]). The LAFI, therefore, provides a sim-
ber volume by accounting for physiologic influences that include stroke volume,pty
ESV
ance
e left
 end 
analo
(maxim
chamtensin inhibitors, loop diuretics, and resting heart rate
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Left Atrial Function and Heart Failure February 14, 2012:673–80(model 2); plus baseline inducible ischemia (model 3);
plus NT-proBNP (model 4); plus diastolic dysfunction,
left atrial volume index, left ventricular ejection fraction,
and left ventricular mass index (model 5). Using the same
models, we also examined the rate of HF hospitalization
using per SD decrease in LAFI.
Most echocardiographic measures were complete or
near complete in all subjects, with the exception of PASP
(missing data: left ventricular ejection fraction [n  0],
left atrial volume index [n  0], left ventricular mass
index [n  6], and diastolic dysfunction [n  19]; PASP
[n  396]). To determine whether the missing data for
PASP was informative, we created a 5-category variable
(PASP in quartile 1, 2, 3, 4, or missing) and entered this
as an indicator variable. We then tested for interaction to
determine whether the association between LAFI and
HF differed by age, sex, diabetes, hypertension, obesity,
AF, or history of HF, with a cut-off of p  0.1 considered
Baseline Characteristics of 855 Participants With Stable Coronaryand Ejection Fraction >50%, by Quartile of Left Atrial Functional InTable 1 B seline Characteristics of 855 Particip nts W th Staband Ejection Fraction >50%, by Quartile of Left Atrial
Quartile I (0.5–29.2 U)
(n  214)
Quartile I
(n
Demographics
Age, yrs 70.0 10.1 65
Male, % 84.1
Caucasian, % 68.2
Medical history
MI 51.2
CHF 25.4
Hypertension 77.9
Diabetes mellitus 26.2
Stroke/TIA 15.4
Atrial fibrillation 16.4
Revascularization 63.9
Angina 59.2
Obesity* 27.6
Current tobacco use 13.6
Laboratory
HDL, mg/dl 46.2 13.9 44
LDL, mg/dl 99.6 32.0 102
eGFR,† mg/dl 71.8 23.5 78
Log NT-proBNP 5.9 1.2 5
Medication use
Aspirin 72.4
Beta-blocker 62.2
Angiotensin-converting enzyme inhibitor 55.6
Statin 65.9
Loop 20.1
Thiazide 15.9
Hemodynamics
SBP, mm Hg 135 21 1
DBP, mm Hg 75 12
Pulse pressure, mm Hg 60 16
Heart rate, beats/min 66.1 12.9 66
Values are mean  SD or %. *Defined as body mass index 30 kg/m2. †Estimated glomerular fi
CHF congestive heart failure; DBP diastolic blood pressure; HDL high-density lipoprotein; LDL l
peptide; SBP  systolic blood pressure; TIA  transient ischemic attack.statistically significant. We also performed a sensitivity
analysis in which we adjusted for interim myocardial
infarction and AF as time-varying covariates to deter-
mine whether the association was independent of interval
development of cardiac events. Assessment of assumption
of proportional hazards using log-minus-log curves and
the Schoenfeld test revealed no violations (22,23).
We have previously found that LV outflow tract–VTI
(24) and LAVI (25), 2 of the component measures used to
derive LAFI, predict HF hospitalization in this cohort.
Therefore, we used c-statistics and chi-square likelihood
ratio testing to compare the discrimination of LAFI with
each of its individual components. Our group has also found
NT-proBNP to be a powerful predictor of HF hospitaliza-
tion in this cohort (26); therefore, we also compared the
discrimination of LAFI with NT-proBNP, which was
log-transformed to meet the assumption of linearity. Cor-
related c-statistics were performed using proportional haz-
t Diseaseoronary Heart Disease
tional Index
–40.8 U)
4)
Quartile III (40.8–53.4 U)
(n  214)
Quartile IV (53.4–160 U)
(n  213) p Value
0.9 65.5 10.3 64.9 11.1 0.001
79.0 77.5 0.29
60.3 53.3 0.01
47.2 54.0 0.54
9.9 11.3 0.001
74.8 80.3 0.37
31.3 27.2 0.65
10.8 12.7 0.54
0.5 0.0 0.001
55.1 51.6 0.05
58.4 61.5 0.78
36.0 35.7 0.21
19.3 23.9 0.05
4.1 46.4 14.3 46.3 13.4 0.63
4.2 106.5 33.2 107.4 32.3 0.07
2.4 79.8 23.4 77.3 22.0 0.001
.2 4.8 1.0 4.5 1.1 0.001
79.4 79.3 0.13
56.5 52.6 0.22
49.1 40.9 0.02
66.8 59.2 0.35
7.9 12.7 0.003
15.0 16.9 0.46
2 134 23 132 18 0.60
1 75 11 75 11 0.93
7 59 18 57 15 0.20
1.2 67.8 11.9 69.0 11.6 0.08
rate (eGFR) by Modification of Diet in Renal Disease equation.Heard xle C
Func
I (29.3
 21
.6 1
82.2
55.6
52.4
11.4
81.2
27.4
14.2
0.5
60.9
62.7
34.6
20.8
.9 1
.9 3
.7 2
.0 1
81.3
59.4
50.0
63.1
12.2
11.7
34 2
75 1
59 1
.9 1
ltration
ow-density lipoprotein; MImyocardial infarction; NT-proBNP N-terminal pro–B-type natriuretic
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February 14, 2012:673–80 Left Atrial Function and Heart Failureards models with post-estimation commands. All analyses
were conducted using STATA (version 11.0, StataCorp,
College Station, Texas).
Results
During a median follow-up of 7.9 years (interquartile
range: 4.8 to 8.1 years), 106 subjects (12.4%) were
hospitalized for HF, of whom 71 (67.0%) had no prior
history of HF. Baseline characteristics of participants
across quartiles of LAFI are displayed in Table 1. The
LAFI was also strongly associated with each of the other
prognostic biomarkers and echocardiographic parameters
(Table 2).
Event rates increased from 5.3 per 1,000 person-years in
the highest quartile of LAFI to 47.0 per 1,000 person-years
in the lowest quartile (Table 3). Kaplan-Meier survival
estimates (Fig. 2) revealed early separation of the event-free
survival curves (within the first few months), which contin-
ued to diverge throughout follow-up. After adjustment for
demographics (age, sex, white race), clinical risk factors
(tobacco use, prior revascularization, history of HF, AF,
low-density lipoprotein, estimated glomerular filtration
rate) medication use (angiotensin inhibitors, loop diuretics),
and heart rate, every SD decrease in LAFI increased the
adjusted hazard of HF 2-fold (HR: 2.0, 95% CI: 1.5 to 2.7;
p  0.001). The association also remained independent
fter further adjustment for log NT-proBNP and a wide
Baseline Measures of Other Known Prognostic Markers by Quartile855 Particip nts With Coronary Heart Disease and Ejection FractioTable 2 Baseline Measures of Other Known Prognostic M ker855 Participants With Coronary Heart Disease and Eje
Quartile I (0.5–29.2 U)
(n  214)
Quartile II (29.3–
(n  214)
LV mass index, g/m2 196 56 189 51
LVEF, % 61.6 63.8
LAVI, ml/m2 43.0 13.5 32.6 6.7
Diastolic dysfunction
None 41.6 63.1
Impaired relaxation 21.0 20.1
Pseudonormal/restrictive 16.8 8.4
PASP, mm Hg 32.0 8.4 29.8 6.9
Inducible ischemia 28.7 21.6
Log NT-proBNP, pg/ml 5.9 1.2 5.0 1.2
Values are mean  SD or %.
LAVI  left atrial volume index; LV  left ventricle; LVEF  left ventricular ejection fraction; PA
Unadjusted Association of Quartiles of Left AtriaWith Heart Failure HospitalizationTable 3 Unadjusted Association QuartilesWith Heart Failure Hospitalization
Person-Time
(Yrs)
Number
of Events
Quartile IV (53.4–160 U) 1,503 8
Quartile III (40.8–53.4 U) 1,461 14
Quartile II (29.3–40.8 U) 1,424 26
Quartile I (0.5–29.2 U) 1,233 58
Total 5,621 106*Log-rank p  0.001.
CI  confidence interval; HR  hazard ratio.ange of other echocardiographic measures (per SD decrease
n LAFI, HR: 1.5, 95% CI: 1.0 to 2.1; p 0.05). Even after
urther adjustment for pulmonary artery systolic pressure,
oint estimates revealed little attenuation (per SD decrease
n LAFI, HR: 1.4, 95% CI: 0.9 to 2.1; p  0.10) (Table 4).
otably, when PASP was entered into the model as a
ategorical predictor with missing data treated as a fifth
ategory, data from the missing category was noninforma-
ive with respect to the association between LAFI and HF
HR: 0.88, 95% CI: 0.4 to 1.9, p  0.88).
To determine whether the association was independent
f interval cardiac events, we also performed a sensitivity
nalysis in which we added interim cardiac events (myocar-
ial infarction and AF) to the adjusted model 2 covariates,
nd found demonstrated no attenuation of the association
per SD decrease in LAFI, HR: 2.2, 95% CI: 1.7 to 2.9;
 0.001).
The association did not vary by age, sex, the presence of
besity, prior history of HF, or AF (p for interaction 0.10
or all). We found significant interactions between LAFI
nd the presence of hypertension (p 0.01) and diabetes (p
0.001). However, stratified analyses revealed the associ-
tion was present among all subsets, and point estimates
ere similar in both strata (hypertension present, n  185,
R: 3.0 per SD decrease in LAFI, 95% CI: 1.1 to 8.3 vs.
ypertension absent, n  670, HR: 2.0 per SD decrease in
AFI, 95% CI: 1.5 to 2.7; diabetes present, n  239, HR:
eft Atrial Functional Index Among0%Quar ile of Lef Atrial Functional Index Among
Fraction >50%
) Quartile III (40.8–53.4 U)
(n  214)
Quartile IV (53.4–160 U)
(n  213) p Value
180 50 172 48 0.001
65.4 66.7 0.001
29.3 6.8 23.8 5.7 0.001
62.6 67.6 0.001
24.3 19.7 0.65
7.0 5.2 0.001
30.9 9.8 28.2 5.9 0.002
18.3 17.0 0.02
4.8 1.0 4.5 1.1 0.001
ulmonary artery systolic pressure.
ctional Indexef Atrial Functional Index
Event Rate
per 1,000 Person-Yrs)
Unadjusted HR
(95% CI) p Value
5.3 — —
9.6 1.8 (0.8–4.3) 0.18
18.3 3.4 (1.6–7.5) 0.001
47.0 8.7 (4.2–18.2) 0.001
18.9of Ln >5s by
ction
40.8 Ul Funof L
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Left Atrial Function and Heart Failure February 14, 2012:673–801.7 per SD decrease in LAFI, 95% CI: 1.2 to 2.4; and
diabetes absent, n  616, HR: 2.3 per SD decrease in
LAFI, 95% CI: 1.6 to 3.4).
To better characterize the predictive ability of LAFI for
incident HF, we also performed a subgroup analysis re-
stricted to subjects with no prior history of HF (n  724)
nd found results were similar to those of the entire cohort:
ubjects with LAFI in the lowest quartile had nearly 6 times
he rate of incident HF hospitalization compared with
ubjects in the highest quartile (adjusted for model 1
ovariates, HR: 5.8, 95% CI: 2.3 to 14.3; p  0.001), and
he rate of HF hospitalization was 80% greater per SD
ecrease in LAFI (HR: 1.8, 95% CI: 1.3 to 2.5, p  0.001).
Figure 2 Proportion Without HF Hospitalization,
Stratified by Quartiles of LAFI
Kaplan-Meier plot of time to heart failure (HF) hospitalization in subjects with
stable coronary heart disease and left ventricular ejection fraction (LVEF)
50% at baseline, stratified by quartiles of the left atrial functional index
(LAFI): solid line  quartile 1; dashed line  quartile 2; dotted line  quartile
3; broken line  quartile 4. The rate of heart failure hospitalization was high-
est in subjects in the lowest quartile of left atrial function, and lowest in sub-
jects in the highest quartile of left atrial function (log-rank p  0.001).
Association of LAFI With Heart Failure HospitaliTable 4 Association of LAFI With Heart Fail
Quartile I Versus IV
Hazard Ratio (95% CI)
Unadjusted 8.7 (4.2–18.2)
Adjusted models
1* 7.6 (3.6–16.0)
2† 7.2 (3.2–16.2)
3‡ 7.5 (2.8–19.8)
4§ 3.4 (1.4–7.8)
5 3.2 (1.2–8.7)
*Adjusted for demographics (age, sex, white race). †Adjusted for
revascularization, history of heart failure, atrial fibrillation, estimated g
(angiotensin-inhibitors, loop diuretics), and resting heart rate. ‡Adjuste
for models 1, 2, and 3 covariates plus log NT-proBNP. Adjusted for m
dysfunction, left atrial volume index, left ventricular ejection fraction, le
was n 769 due to missing data for race (n 1), tobacco (n 3), reva
(n  4), diastolic dysfunction (n  19), left ventricular mass index (n  6), re
CI  confidence interval; LAFI  left atrial functional index.iven the marked preponderance of AF in the lowest
uartile of LAFI, we also performed a subgroup analysis
imited to only subjects without AF (n  818), which
emonstrated no difference compared with the entire cohort
adjusted for model 2 covariates, HR: 6.8, 95% CI: 3.0 to
5.0; p  0.001), and the rate of HF hospitalization was
-fold greater for every 1 SD decrease in LAFI (HR: 2.0,
5% CI: 1.5 to 2.7, p  0.001).
The discrimination of LAFI for HF hospitalization was
lso superior to each of its individual components (unad-
usted c-statistics, LAFI 0.73 vs. LVOT-VTI 0.60 [p for
omparison 0.001], LA emptying fraction 0.65 [p 
.001], and LAVI 0.69 [p  0.07]). Cox models also
evealed that LAFI provides prognostic value incremental to
ts component measures (chi-square likelihood ratio testing,
 0.001 for all).
We also compared c-statistics to determine the incre-
ental prognostic value of LAFI when used in conjunction
ith clinical risk factors and log NT-proBNP. The addition
f LAFI to clinical risk factors was significantly more
redictive of HF hospitalization than clinical risk factors
lone (0.81 for clinical risk factors plus LAFI vs. 0.77 for
linical risk factors alone; p  0.001), or clinical risk factors
lus log NT-proBNP (0.85 for clinical risk factors plus log
T-proBNP plus LAFI vs. 0.81 for clinical risk factors plus
og NT-proBNP alone; p  0.001).
iscussion
n a cohort of 855 predominantly male out-patients with
table coronary artery disease and preserved baseline ejection
raction (50%), we found that LA dysfunction, as mea-
ured by LAFI, is associated with HF hospitalization. This
ssociation was independent of age, sex, race, traditional
ardiovascular risk factors, heart rate, inducible ischemia,
T-proBNP, and other commonly used echocardiographic
arameters (diastolic dysfunction, left atrial volume index,
n, With Multivariate Adjustmentospitalization, With Multivariate Adjustment
Per SD Decrease in LAFI
alue Hazard Ratio (95% CI) p Value
.001 2.6 (2.1–3.3) 0.001
.001 2.4 (1.9–3.0) 0.001
.001 2.0 (1.5–2.7) 0.001
.001 2.0 (1.5–2.7) 0.001
.005 1.4 (1.1–1.9) 0.02
.02 1.5 (1.0–2.1) 0.05
1 covariates plus cardiovascular risk factors (tobacco use, prior
lar filtration rate, low-density lipoprotein cholesterol), medication use
odels 1 and 2 covariates plus baseline inducible ischemia. §Adjusted
1 through 4 covariates plus echocardiographic parameters (diastolic
icular mass index). The total number of participants in the final model
zation (n 1), low-density lipoprotein (n 22), history of heart failurezatioure H
p V
0
0
0
0
0
0
model
lomeru
d for m
odels
ft ventr
scularisting heart rate (n  1), and NT-proBNP (n  29).
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index).
Left atrial functional index. The LAFI is unique among
means of characterizing the LA in that it combines expressions
of atrial reservoir function (fractional change), adjusted atrial
volume (LAVI), and stroke volume (VTI). For example, a
patient with a large LA due to bradycardia will be correctly
characterized by LAFI as having normal atrial function be-
cause both fractional change and VTI are increased.
The left atrium and HF. Prior studies have demonstrated
a correlation between LA volume and diastolic dysfunction
(27,28). Left atrial volume has also been shown to predict
incident HF (29). Both rest and reserve LA function have
been implicated in HF events in cross-sectional studies of
subjects with HFpEF (14,30). Recent data have also found
subjects with HFpEF to have increased atrial contribution
to LV filling as a compensatory response to impaired early
LV filling during exercise (31). Our demonstration of a
longitudinal association between LA function and HF in
subjects with preserved baseline EF complements these
observations.
LA function in AF. Unlike other echocardiographic mea-
sures of LA function, the LAFI is unique in that it can be
measured even in subjects with AF (16). Atrial fibrillation/
flutter is a common comorbidity in subjects with HF;
therefore, LAFI is an attractive parameter in this popula-
tion. As expected, AF was far more common among
subjects in the lowest quartile of LAFI compared with those
in the highest 3 quartiles of LAFI. This is consistent with
our previous finding that LAFI is low in subjects with AF
and increases upon successful cardioversion to sinus rhythm
(16). Although LAFI is lower in the setting of AF, we
found that the association between LAFI and HF hospital-
ization was also independent of AF.
Other potential mechanisms of HFpEF. Although LA
dysfunction is 1 potential mechanism of HFpEF, several
other possible mediators have also been proposed, including
inducible ischemia (32), elevated PASP (33), ventricular-
arterial stiffening (34), and higher LV mass index (10,11,14).
Our findings suggest that the association between LA
dysfunction and HF hospitalization in subjects with pre-
served baseline EF is independent of these factors.
Clinical implications. Because the LA contributes up to
30% of stroke volume in healthy persons, its impairment
may precipitate HF. Alternatively, LA dysfunction may
simply be a consequence of other pathophysiologic mecha-
nisms that cause HF. If causal, early efforts to prevent or
arrest LA dysfunction may be beneficial for persons with
high-risk clinical features. Notably, angiotensin inhibition,
which had shown potential to reverse atrial remodeling in
animal models (35), did not reduce mortality in clinical
trials of subjects with HFpEF (8,9,36). However, other
therapies that have shown promise for reversal of atrial
remodeling, such as aldosterone antagonists (37)—currently
being evaluated for the treatment of HFpEF in the ongoing
TOPCAT (Treatment Of Preserved Cardiac function heartfailure with an Aldosterone anTagonist) trial—restoration
of sinus rhythm (38,39), or device therapies (40) could be
considered. Regardless of whether improvement of LA
function could affect outcomes, the LAFI provides prog-
nostic value that is incremental to clinical risk factors and
NT-proBNP, and therefore may be useful in risk stratifica-
tion to identify patients with preserved baseline EF who are
at high risk of HF hospitalization.
Study limitations. First, our cohort was composed of
predominantly men, which may limit generalizability to
women. However, testing for effect modification by sex
revealed no difference in the association. Second, although
we restricted our analysis to subjects who had a preserved
EF at baseline, it is possible that EF or diastolic function
may have declined in some subjects before HF hospitaliza-
tion. However, adjustment for the presence of inducible
ischemia at baseline and interim cardiac events (myocardial
infarction and AF) did not attenuate the association. Third,
electrocardiogram data at the time of HF failure presenta-
tion was not available; however, adjustment for interim
development of AF based on electrocardiograms at year 5
demonstrated no change in the association. Fourth, the
cutpoint of 50% for EF is widely used, but subjects in the
lowest quartile probably include a proportion with estab-
lished systolic dysfunction. However, further adjustment for
EF demonstrated no significant change in the association.
Fifth, we evaluated a single measure of resting LA function.
Other echocardiographic measures of LA function, includ-
ing Doppler tissue imaging, segmental atrial function as-
sessment, strain, strain rate, and atrial response to exercise
were not examined. Finally, some degree of over-fitting is
present in the larger multivariate models; however, results
were consistent with the more parsimonious models.
Conclusions
We found that LA dysfunction, as measured by the LAFI,
is strongly and independently associated with HF hospital-
ization in patients with preserved baseline EF and stable
coronary heart disease. This association remained indepen-
dent even after adjustment for a wide range of clinical and
echocardiographic covariates, and the prognostic value of
the LAFI was incremental to clinical risk factors and
NT-proBNP. The LAFI may be useful for HF risk strati-
fication, and LA dysfunction may be a potential therapeutic
target.
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